

1 **Title: B cell depletion attenuates CD27 signaling of T helper cells in multiple**
2 **sclerosis**

3 **Authors:** Can Ulutekin^{1,†}, Edoardo Galli^{1,2,†}, Mohsen Khademi³, Ilaria Callegari², Fredrik Piehl³,
4 Nicholas Sanderson², Massimo Filippi⁴, Roberto Furlan⁴, Tomas Olsson³, Tobias Derfuss², Florian
5 Ingelfinger^{1,‡} & Burkhard Becher^{1,‡,*}

6 **Affiliations:**

7 ¹Institute of Experimental Immunology, University of Zurich; Zurich, Switzerland.

8 ²Department of Biomedicine, University Hospital Basel; Basel, Switzerland.

9 ³Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet; Stockholm,
10 Sweden.

11 ⁴Clinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience,
12 San Raffaele Scientific Institute; Milan, Italy.

13 † These authors contributed equally.

14 ‡ These authors contributed equally.

15 * Correspondence to: becher@immunology.uzh.ch

16

17 **One Sentence Summary:** B cell depletion contracts follicular T helper cells, displaces memory-
18 to-naïve ratio and impairs CD27 signaling in T helper cells.

19 **Abstract:** Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
20 (CNS). Traditionally, MS was held to be a T-cell mediated disease, but accumulating evidence
21 during the last decade also highlighted the crucial importance of B cells for the disease progression.
22 Particularly, B cell depleting therapies (BCDTs), have demonstrated striking efficacy in
23 suppressing inflammatory disease activity in relapsing-remitting MS. However, a detailed
24 understanding of the role of B cells in the pathogenesis of MS is still lacking, and by extension
25 also the mechanism of action of BCDTs. In this longitudinal multi-center study, we investigated
26 the impact of BCDTs on the immune landscape in MS patients using high-dimensional single-cell
27 immunophenotyping (cytometry by time-of-flight; CyTOF). Algorithm-guided analyses revealed
28 phenotypic changes in the newly reconstituted B cell compartment after BCDT, as well as a
29 marked specific reduction of circulating T follicular helper (Tfh) cells with a concomitant
30 upregulation of CD27 surface expression in memory T helper cells and Tfh cells. These findings
31 indicate a costimulatory mechanism in the CD27/CD70 signaling pathway, through which B cells
32 sustain the activation of pathogenic T cells. Disrupting the CD27/CD70 signaling axis via BCDTs
33 provides a potential explanation for its clinical efficacy.

34 **Main Text:**

35 **INTRODUCTION**

36 MS is an immune-mediated disease, characterized by demyelination of the CNS, where disease
37 progression results from a complex interplay between partially understood neurodegenerative
38 processes and inflammatory episodes. Traditionally, MS was considered a T cell-mediated disease
39 based on evidence inferred from animal models of neuroinflammation (1, 2). However, therapies
40 targeting exclusively T lymphocytes in patients demonstrated only weak clinical efficacy (3). More
41 recent evidence supported the involvement of B cells in the disease pathogenesis and progression
42 of MS. One of the most convincing findings highlighting the critical role of B cells in the disease
43 has been the high response rate of BCDTs in ameliorating MS (4–6). These findings have shifted
44 the perception of the disease towards mechanisms in which the interplay between B and T cells
45 takes a more prominent role (7).

46 Despite the impressive clinical efficacy of BCDTs in suppressing inflammatory disease activity in
47 MS, their precise mechanism of action remains unclear and is an area of active research (8).
48 Removal of the total circulating immunoglobulin fraction via plasmapheresis (9, 10), or interfering
49 with potentially pathogenic antibodies via intravenous immune globulin (IVIG) injections (11–13)
50 have shown limited efficacy. Furthermore, anti-CD20-mediated BCDTs do not target plasma cells
51 and have minimal effects on antibody titers (6). Thus, it appears likely that the success of BCDTs
52 depends on B-cell activities other than antibody production, such as cytokine secretion, antigen
53 presentation or co-stimulation. Several studies report upregulation of proinflammatory cytokines
54 and a concomitant downregulation of immunoregulatory cytokines in B cells of MS (14–20). Apart
55 from cytokine production, B cells are antigen-presenting cells (APCs) and can efficiently prime T
56 cells (21). Accordingly, polymorphisms in major histocompatibility complex (MHC) genes
57 demonstrate the strongest association with MS susceptibility, particularly those encoding for class
58 II MHC molecules (22–25).

59 The characterization of the replenished B cell population after depletion with BCDTs has been
60 examined before (14, 16, 19), but studies investigating the immune compartment as a whole are
61 missing. Here, we systematically investigated the effects of BCDTs on the peripheral immune
62 landscape in MS patients. We used high-dimensional mass cytometry in conjunction with
63 unsupervised clustering to analyze the systemic immune compartment of MS patients after BCDTs
64 in a longitudinal manner. B cell depletion evoked alterations in CD4⁺ T cell composition and
65 expression of costimulatory molecules suggesting that the cell-to-cell interactions between B and
66 T cells play a key role during MS immunopathology that could be compromised using BCDTs.
67 Our study thereby addresses the enigmatic role of B cells in MS pathology and suggests a
68 costimulatory mechanism of action for B cell depleting agents in MS patients.

69

70 **RESULTS**


71 **The replenished B cell compartment is phenotypically altered in MS**

72 To characterize the immune landscape of MS patients after BCDT, we collected longitudinal
73 peripheral blood mononuclear cell (PBMC) samples of MS patients undergoing BCDT (table 1).
74 The samples were analyzed by two partially overlapping mass cytometry panels in order to deeply
75 interrogate cellular states and subsets associated with the clinical success of BCDT.
76 Dimensionality reduction using Uniform Manifold Approximation and Projection (UMAP) and

77 unsupervised FlowSOM clustering identified B cells, CD4⁺ T cells, CD8⁺ T cells, regulatory T
 78 (Treg) cells, $\gamma\delta$ T cells, natural killer (NK) cells and myeloid cells (fig. 1, A and B).

79 To assess the kinetics of the impact of BCDTs on discrete B cell subsets, B cells were dissected
 80 into canonical B cell subsets: memory, naïve, marginal zone-like (MZ-like), and plasmablasts
 81 (fig.1C, and fig. S1A). In line with previous reports (26), each of the investigated B cell subsets
 82 were efficiently depleted after treatment infusions (fig. 1D). To assess how the newly repopulating
 83 B cell compartment differed following BCDT, we compared the B cell compartment before
 84 therapy initiation to timepoints, where a replenishment could be observed (8-45 weeks since last
 85 infusion, median 22; 106-7041 cell counts, median 399). Consistent with previous reports (27) we
 86 observed a decrease in the frequency of memory B cells and an increase in the frequency of naïve
 87 B cells (fig. 1E).

88 Newly replenished B cells revealed a downregulation of CCR7, the chemokine receptor essential
 89 for migration to lymphoid tissues (28) and CD268 and CD19 (fig. 1F and fig. S1B). CD268,
 90 encoding for the B-cell-activating receptor (BAFF-R), is a crucial regulator of B- and T-cell
 91 activity (29), however, failing evaluation as a pharmacological target in MS (30), in spite of
 92 compelling evidence from preclinical studies (31, 32). CD19 is a critical protein of the CD19
 93 complex, involved in the amplification of B cell receptor signaling and subsequent B cell
 94 activation (33, 34).



95
 96 **Fig. 1. BCDTs deplete B cells efficiently and alter the B cell phenotype after reconstitution.** (A) UMAP of 52,500
 97 cells randomly sampled from the combined dataset. The number of sampled cells was constant across samples. Color
 98 code indicates the main clusters generated through clustering and manual annotation. (B) Heatmap showing the
 99 median marker expression across the identified main clusters. (C) Heatmap shows the median marker expression
 100 across the identified B cell sub-clusters. (D) Frequency of B cell subsets among total cells across time after infusion.
 101 Points represent individual samples. The line represents the conditional mean of B cell subset frequency. (E) Pie chart
 102 showing the composition of distinct subsets within the B cell compartment before (left) and after (right) treatment.

103 The after-treatment B cell compartment consists of late timepoint representing the replenishing B cell compartment.
104 (F) Bar plot displaying changes in marker expression of newly populating B cells in MS. Marker expression changes
105 visualized through paired Wilcoxon effect size. Color code indicates up- or downregulation.

106

107 **B cell depletion reduces the frequency of T follicular helper cells in MS patients**

108 To have a broad overview of the impact of BCDTs on the immune compartment, we investigated
109 the frequency of distinct immune cell populations in MS patients before and after therapy. To
110 account for the bias elicited by the depletion of B cells, we computationally removed them from
111 our analysis and normalized the frequencies accordingly. We observed that the canonical immune
112 cell populations were not altered by BCDT treatment suggesting a more nuanced effect of the
113 treatment on the immune landscape (fig. S1C).

114 B- and T-cell interactions have a fundamental role during the immunopathology of MS (35), and
115 interference with these interactions could partially account for the clinical efficacy of BCDTs. To
116 better characterize the impact of BCDTs on the T cell compartment we defined five distinct CD4⁺
117 T cell subsets in the peripheral blood of MS patients; central memory, effector memory, naïve, T
118 follicular helper (Tfh) and CD103⁺ cells (fig. 2A). For each subset we longitudinally analyzed the
119 shift in the frequency after BCDT (fig. 2B). We observed a significant decrease in the frequency
120 of Tfh cells in response to BCDT treatment. Circulating Tfh cells have been reported to be
121 increased in the blood of MS patients and a reduction of these has been associated with a remission
122 of the disease (36, 37). These observations suggest that BCDTs may indirectly deplete potentially
123 pathogenic Tfh cells and highlight the interdependence of these with B cells. Consistent with
124 previous observations (38), when comparing changes in the naïve-to-memory ratio, we observed a
125 shift from memory towards naïve Th cells (fig. 2C).

126 Analogous, to the CD4⁺ T cell compartment, we defined distinct subsets within the CD8⁺ T cell
127 compartment (fig. S2A). Analyzing the shift in the frequency of these subsets in BCDT treated
128 MS patients, we observed that these were largely unaffected in response to BCDT treatment (fig.
129 S2B). Accordingly, the ratio of naïve-to-memory cytotoxic T cells was unchanged between
130 untreated and treated MS (fig. S2C). Despite the dominance of CD8⁺ T cells over CD4⁺ T cells in
131 lesions of MS patients and their potential involvement in the immunopathology of MS (39–41),
132 these results point towards a highly selective influence of BCDTs on the Th cell compartment.

133


134 **B cell depletion leads to selective increase in CD27 expression across memory Th cell subsets**

135 Next, we assessed whether phenotypic alterations in CD4⁺ T cell subsets could be associated with
136 BCDTs. To this end, we assigned each marker to one of three distinct, mutually exclusive groups:
137 surface activation markers, surface localization markers and cytokines. For each subset we
138 compared longitudinally how the expression levels changed in response to B cell depletion (fig.
139 2D). This approach revealed a selective disparity in CD27 expression across T helper (Th) cell
140 subsets, where we observed increased surface CD27 across central and effector memory Th cells
141 as well as Tfh cells (fig. 2, E and F). In relation to our observations, soluble CD27 (sCD27) in the
142 cerebrospinal fluid (CSF) is a prognostic biomarker in MS and its protein levels correlate directly
143 with disease severity (42–44).

144 The costimulatory molecule CD27 is part of the tumor necrosis factor receptor superfamily
145 (TNFRSF) and its ligand CD70 is expressed by APCs (45–48). CD27 signaling leads to the

146 induction of pro-survival pathways(49, 50) and supports the efficient expansion and differentiation
147 of activated T cells (51–54). CD27 expression is transiently upregulated upon TCR-engagement
148 (55–57) and proteolytically cleaved and released as soluble CD27 (sCD27) upon sustained signaling
149 (42, 58, 59). Surface expression of CD27 therefore naturally declines along the T cell differentiation
150 path (47), with naïve T cells having the highest expression and more differentiated subsets showing
151 a lower expression. Thus, higher surface CD27 expression levels may be a result of impaired
152 interaction due to the depletion of CD70 expressing B cells and could represent an attenuation of
153 CD27 signaling. Indeed, when we examined surface CD27 levels along the differentiation path of
154 Th cells we observed an overall increased expression after BCDT (fig. 2G). This effect was most
155 pronounced in more differentiated Th cells (fig. 2H). In summary, elevated surface levels of CD27
156 is likely the consequence of decreased engagement with CD70 on B cells, which could partially
157 hamper the pathogenic potential of Th cells.

158 Next, we assessed changes in marker expression in the CD8⁺ T cell compartment analogous to the
159 previous analysis for the CD4⁺ T cells. None of the analyzed markers appeared dysregulated after
160 BCDT in the cytotoxic T cell compartment (fig. S2D). Specifically, CD27 expression levels during
161 cytotoxic T cell differentiation followed a similar expression pattern as observed for the CD4⁺ T
162 cell counterpart but did not reveal any changes as a result of BCDT, again highlighting the
163 selectivity of BCDT on Th cell compartment (fig. S2, E and F).



164

165 **Fig. 2. BCDTs alter the peripheral CD4⁺ T cell landscape of MS patients.** (A) Heatmap showing median
 166 expression of lineage markers across identified CD4⁺ T cell subsets. (B) Violin plots showing changes in the
 167 frequency across CD4⁺ T cell subsets in BCDT treated MS. Paired Wilcoxon rank-sum test and Benjamini-Hochberg
 168 correction was applied. (C) Violin plots showing changes in the naive to memory ratio within the CD4⁺ T cell
 169 compartment. Paired Wilcoxon rank-sum test was applied. (D) Radar plots showing changes in the marker expression
 170 of CD4⁺ T cell subsets in BCDT treated MS. Values correspond to $-\log_{10}(p\text{-value})$ and were adjusted with the
 171 Benjamini-Hochberg correction. Inner circle color annotations denote each respective subset. Bar color denotes the
 172 upregulation or downregulation of the respective marker. Marker order is consistent across subsets. (E) Various
 173 heatmaps showing CD27 expression of each MS patient before and after B cell depleting treatment. Each heatmap
 174 denotes a different CD4⁺ T cell subset. CD27 expression on each heatmap normalized by transforming the range of
 175 expression to maximal separation within 0 and 1 values. (F) Violin plots showing changes in CD27 expression across
 176 CD4⁺ T cell subsets in BCDT treated MS. P values correspond to the paired Wilcoxon rank-sum test applying a
 177 Benjamini-Hochberg correction. (G) Median CD27 expression along CD4⁺ T cell subsets of the MS patients. Points


178 are individual sample values. Color code denotes patient values before or after treatment. **(H)** Percent fold-change in
179 CD27 expression along CD4⁺ T cell subsets of the MS patients, depicted in percent changes. Shaded area represents
180 the 95 % confidence interval.

181
182 **Analysis of independent cohort confirmed the impact of BCDTs on circulatory Tfh and CD27**
183 **expression**

184 Next, we investigated whether the selective changes of BCDT on the Th cell compartment could
185 be validated in an independent cohort derived from a distinct clinical center (table 2). This
186 confirmed the reduction of circulating Tfh cells in response to BCDTs in an additional dataset (fig.
187 3A). When analyzing changes in CD27 expression across CD4⁺ memory T cell and Tfh cell
188 subsets, we confirmed our previous result and observed significant upregulation in surface CD27
189 levels in central memory T cells and Tfh cells but not effector memory T cells (fig. 3B). In
190 conclusion, using an independent cohort of BCDT treated MS patients, we confirmed our findings
191 that Tfh cells specifically decrease in frequency and surface CD27 levels of central memory T
192 cells and Tfh cells increase after treatment.

193
194 **BCDT in myasthenia gravis patients induced CD27 expression in Tfh cells**

195 To assess whether the selective influence of BCDTs on the Th cell compartment was specific to
196 MS pathophysiology or a universal feature of BCDTs. We next analyzed the influence of BCDTs
197 on the CD4⁺ T cell compartment in myasthenia gravis (MG) patients in an independent cohort
198 (table 3). For comparative purposes, these patients were selected to be treatment naïve to immune
199 suppressants, except for exposure to low to moderate doses of corticosteroids in some cases.
200 Longitudinal comparison of Tfh cell frequencies revealed a decreasing trend that did not reach
201 statistical significance (fig. 3C). Similarly, we evaluated surface CD27 levels in memory T cells
202 and Tfh cells in response to BCDTs. Consistent with the MS findings, we observed a trend towards
203 upregulation (fig. 3D). However only in Tfh cells this measurement reached statistical
204 significance. The number of MG patients analyzed here is relatively small, thus limiting the
205 statistical power. Despite the disparity in clinical efficacy of BCDTs in MS and MG (60, 61), we
206 can conclude that upregulation of CD27 in Tfh cells is a universal hallmark of the therapy.



207

208 **Fig. 3. The altered CD4⁺ T cell landscape is consistent across cohorts.** (A) Violin plot showing the frequency in
209 CD4⁺ Tfh cells in B cell depleted MS patients of the validation cohort. Paired Wilcoxon rank-sum test was applied.
210 (B) Violin plots showing changes in CD27 expression across CD4⁺ memory and Tfh cells in B cell depleted MS
211 patients of the validation cohort. Paired Wilcoxon rank-sum test was applied. (C) Violin plot showing the frequency
212 in CD4⁺ Tfh cells in B cell depleted MG patients of the validation cohort. Paired Wilcoxon rank-sum test was applied.
213 (D) Violin plots showing changes in CD27 expression across CD4⁺ memory and Tfh cells in B cell depleted MG
214 patients of the validation cohort. Paired Wilcoxon rank-sum test was applied.

215

216 DISCUSSION

217 BCDT is one of the most impactful therapeutic advancements for the treatment of MS to date (7).
218 Nevertheless, the mechanism by which BCDTs mediate their clinical efficacy remains entirely
219 unknown. As mentioned above, the cardinal feature of B cells, namely the production of antibodies
220 cannot be responsible for the effect in MS. Nevertheless, it is surprising that the effect that BCDT
221 has on disease development has not yet been revealed. Here, we sought to provide an unbiased
222 roadmap of the systemic immune compartment in response to the elimination of B cells. Given
223 that B cell depletion eliminates 5 to 10 % of lymphocytes from the PBMC compartment, the
224 subtlety of the consequences for the remaining immune compartment is surprising. To better
225 understand how BCDT alters the non-B-cell immune compartment, we designed an
226 immunophenotyping protocol combined with a comprehensive algorithm-guided analysis.

227 Here, we demonstrated a selective influence of BCDTs on the CD4⁺ T cell compartment in the
228 peripheral blood of MS patients. We observed an upregulation of surface CD27 levels along the
229 Th cell differentiation path in response to BCDTs, that was most pronounced in memory Th cells
230 and Tfh cells. Upon sustained signaling CD27 is cleaved into its soluble form. Therefore its

231 upregulation in response to BCDT could be indicative of an attenuation of the CD27/CD70
232 signaling pathway. It is conceivable that dysregulated interactions between B and Th cells act as
233 drivers of MS and depletion of B cells could impair these interactions. In parallel to its impairment
234 upon BCDTs, loss of surface CD27 molecules in T cells is a molecular feature of terminal
235 differentiation (56, 62). The BCDT induced upregulation of surface CD27 may imply an
236 impediment in the activity of Th cells, partially explaining the efficacy of the therapies.

237 In line with this hypothesis, increased levels of sCD27 in the CSF is a well-established biomarker
238 of MS (42) and has been positively correlated to relapse rates (63). Furthermore, sCD27 in the CSF
239 of MS patients was highly predictive of active intrathecal inflammation (43). Reduced sCD27
240 levels in the CSF has been reported in response to common therapies in MS, including BCDTs
241 (64–66). Additional support of the involvement of the CD27/CD70 pathway in MS comes from
242 studies using preclinical models of MS. It was shown that administration of anti-CD70 monoclonal
243 antibody significantly repressed experimental autoimmune encephalomyelitis (EAE) and Theiler's
244 murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) and resulted in the
245 reduction of clinical scores as well as inflammation and demyelination levels (67, 68). Similarly, in
246 a transgenic mouse, where the T-cell receptor recognizes the myelin oligodendrocyte glycoprotein,
247 constitutive CD70 expression on B cells increased susceptibility of mice towards spontaneous
248 EAE development (69).

249 In addition to a dysregulation in the B cell/T cell interface via the CD27/CD70 axis, we observed
250 a significant decrease in the frequency of Tfh cells in MS patients, after treatment with BCDTs.
251 Given the central role of Tfh cells in providing costimulatory maturation and proliferation signals
252 to B cells, their decrease in frequency after depletion of B cells highlights the importance of direct
253 cell-cell interactions during the immunopathology of MS. Numerous studies underscore the
254 importance of Tfh cells in MS pathophysiology (36, 37, 70). CXCL13, a chemokine involved in the
255 migration of B cells and Tfh cells (71, 72), is found to be elevated in the CSF of MS patients (73)
256 and predictive of a more severe disease course (74). Furthermore, rituximab treatment has been
257 shown to decrease CXCL13 as well as T cells in the CSF, in a proportional manner (75). CXCL13
258 is prominently produced by actively demyelinating lesions but not by chronic inactive lesions (76–
259 78). Finally, increased levels of circulating Tfh cells have been reported in MS and found to be
260 reduced in patients with complete remission (36, 37).

261 In conclusion, our study highlights a highly selective influence of BCDTs on the Th cell
262 compartment of MS patients. These findings suggest that BCDTs may cause a partial blockade in
263 the full effector differentiation of Th cells due to compromised CD27/CD70 signaling.
264 Furthermore, our analysis reports a significant reduction in the frequency of Tfh cells and
265 emphasizes their involvement in MS as suggested by others. Our study thereby identifies a
266 potential mechanism of action for BCDTs and reveals important insights into the pathophysiology
267 of MS.

268 It was vital for this study, to include patients treated with BCDT and to obtain samples prior as
269 well as after the treatment induction. This fact is mainly responsible for the relatively limited
270 sample size and therefore limited statistical power. Nevertheless, our findings could be validated
271 in patient cohorts obtained from two independent clinical centers. Current untargeted single-cell
272 technologies (e.g. RNA-seq) are limited in their throughput and resolution, but they could have
273 potentially revealed additional alterations driven by BCDT. As a compromise here we used
274 CyTOF, which allowed for a combined analysis of multiple barcoded patient samples. Even though
275 the dynamic range for detection of protein expression and reproducibility across the samples is

276 very good, the quasi-targeted nature of CyTOF may create a bias. Finally, this study would have
277 benefitted from access to longitudinal CSF samples, which likely are more reflective of the events
278 that occur within inflammatory CNS lesions.

279

280 MATERIALS AND METHODS

281 Study design

282 The objective of this study was to investigate the immune landscape of MS patients in response to
283 BCDTs. For this purpose longitudinal samples, before and after therapy induction, were analyzed
284 via CyTOF. Two overlapping mass cytometry panels were applied interrogating various co-
285 stimulatory and trafficking molecules, cytokines, and lineage markers. Data was acquired in two
286 independent runs and normalized through batch correction. A computational pipeline comprising
287 clustering, dimensionality reduction and statistical analyses was employed in order to retrieve
288 phenotypic immune alterations in response to BCDT. Our findings were validated in an
289 independent cohort from a distinct clinical center.

290

291 Longitudinal PBMC samples of MS patients during BCDT in the discovery cohort

292 For the initial discovery cohort longitudinal PBMC samples of MS patients before and after BCDT
293 were collected at the MS center of the University Hospital Basel (Table 1). MS diagnosis was
294 based on the revised McDonald criteria⁽⁷⁹⁾. All patients gave written informed consent, with
295 ethical oversight by the Ethikkommission beider Basel (Ref.Nr. EK: 49/06).

296 In the discovery cohort samples from multiple timepoints were available. Inclusion criteria for the
297 discovery cohort included longitudinal patient samples, appropriate B cell depletion after BCDTs
298 as well as no previous disruptive treatments. When performing longitudinal statistical analyses,
299 samples from timepoints closest to initial treatment were chosen. Samples containing the highest
300 B cell frequency after treatment were chosen for the analysis of repopulating B cells and a 100-
301 cell cut-off was applied. As such 8 patients out of 12 were qualified.

302

303 **Table 1:** Clinical and demographic characteristics of patients in the discovery cohort.

ID	Diagnosis	Age Range	Sex	Treatment	Previous Treatment	Cycle of Treatment	Days Since Last Treatment	Days Since First Treatment
1	RRMS	31 - 40	M	Ocrelizumab	None	2	146	160
2	RRMS	31 - 40	F	Ocrelizumab	None	2	148	162
3	RRMS	21 - 30	M	Ocrelizumab	Interferon β	2	57	71
4	RRMS	21 - 30	F	Ocrelizumab	None	2	43	57
5	PPMS	61 - 70	F	Rituximab	None	6	126	877
6	PPMS	51 - 60	M	Ocrelizumab	None	3	117	320
7	RRMS	41 - 50	F	Ocrelizumab	None	2	43	57
8	RRMS	21 - 30	F	Ocrelizumab	None	2	154	168
9	RRMS	31 - 40	F	Ocrelizumab	None	2	93	106

10	RRMS	51 – 60	F	Ocrelizumab	None	2	182	196
11	PPMS	41 – 50	F	Rituximab	None	3	98	306
12	RRMS	51 - 60	M	Rituximab	None	3	92	468

304

305 **Longitudinal PBMC samples of MS and MG patients during BCDT in the validation cohort**

306 Cryopreserved longitudinal PBMC samples of MS and MG patients before and after BCDT in the
 307 validation cohort were collected at the Department of Neurology at Karolinska University Hospital
 308 (Table 2, Table 3). MS patients were diagnosed according to the revised McDonald criteria⁽⁷⁹⁾.
 309 The MG diagnosis was confirmed by at least 2 of the following: a positive AChR antibody test
 310 result, an abnormal electrophysiological test result (repetitive nerve stimulation and/or single fiber
 311 electromyography) consistent with MG, and/or a clinically significant response to an oral or
 312 intravenous AChEI test (per treating physician’s opinion). All patients had given written informed
 313 consent and the study has been approved by the regional ethical review board of Stockholm (MS
 314 dnr. 2009/2107-21/2, last amendment dnr. 2022-03650-02; MG 2016-827-31).

315 In the validation cohort each patient had one timepoint before treatment and one timepoint after
 316 treatment. Inclusion criteria for the validation cohort included appropriate B cell depletion after
 317 BCDTs.

318

319 **Table 2:** Clinical and demographic characteristics of MS patients in the validation cohort.

ID	Diagnosis	Age Range	Sex	Treatment	Previous Treatment	Cycle of Treatment	Days Since Last Treatment	Days Since First Treatment
1	RRMS	21 – 30	M	Rituximab	None	1	185	185
2	RRMS	31 – 40	F	Rituximab	None	1	182	182
3	RRMS	21 - 30	F	Rituximab	None	3	112	475
4	RRMS	41 – 50	F	Rituximab	Cortisone	3	91	455
5	RRMS	21 – 30	F	Rituximab	Cortisone	2	188	360
6	RRMS	21 – 30	F	Rituximab	None	3	171	534
7	RRMS	21 – 30	F	Rituximab	None	3	108	468
8	RRMS	31 – 40	F	Rituximab	None	2	234	463
9	RRMS	41 – 50	M	Rituximab	None	6	126	1050
10	RRMS	31 – 40	M	Rituximab	None	6	12	925
11	RRMS	51 – 60	M	Rituximab	None	5	127	851
12	RRMS	51 – 60	F	Rituximab	None	2	27	207
13	RRMS	41 – 50	M	Rituximab	None	1	130	130
14	RRMS	31 - 40	M	Rituximab	Cortisone	1	90	90

320

321 **Table 3:** Clinical and demographic characteristics of MG patients in the validation cohort.

ID	Serology	Age Range	Sex	Treatment	Previous Treatment	Cycle of Treatment	Days Since Last Treatment	Days Since First Treatment
15	LRP4	61 - 70	M	Rituximab	None	1	197	197
16	AChR	41 - 50	M	Rituximab	Mestinon	1	215	215
17	LRP4	51 - 60	M	Rituximab	Cortisone, Mestinon	1	159	159
18	AChR	21 - 30	F	Rituximab	None	1	91	91
19	AChR	41 - 50	F	Rituximab	None	1	91	91
20	Negative	51 - 60	M	Rituximab	None	1	115	115
21	Negative	41 - 50	F	Rituximab	None	1	226	226
22	AChR	71 - 80	M	Rituximab	None	1	244	244

322

323 **Statistical analysis**

324 All statistical analyses were done in R. Wilcoxon effect size calculations were done with the R
325 package “rstatix” and were used in the analysis of marker changes in the replenished B cell
326 compartment. Non-parametric paired Wilcoxon rank-sum test from the R package “stats” was used
327 to compare two groups unless stated otherwise. Controlling for multiple comparisons was
328 accomplished with the Benjamini-Hochberg approach also from the “stats” package.

329 **Study approval**

330 All donors had given written informed consent and the study was approved by the regional ethical
331 review board of Stockholm (MS dnr. 2009/2107-21/2, last amendment dnr. 2022-03650-02; MG
332 2016-827-31) and Basel (Ref.Nr. EK: 49/06), respectively.

333

334 **SUPPLEMENTARY MATERIALS**

335 Materials and Methods

336 Figs. S1 and S2

337 Tables S1 to S3

338 References (80–86)

339

340 **References and Notes:**

- 341 1. A. Bar-Or, The Immunology of Multiple Sclerosis. *Semin Neurol* 28, 029–045 (2008).
- 342 2. C. A. Dendrou, L. Fugger, M. A. Friese, Immunopathology of multiple sclerosis. *Nat Rev Immunol* 15, 545–558
343 (2015).
- 344 3. B. W. van Oosten, M. Lai, S. Hodgkinson, F. Barkhof, D. H. Miller, I. F. Moseley, A. J. Thompson, P. Rudge, A.
345 McDougall, J. G. McLeod, H. J. Ader, C. H. Polman, Treatment of multiple sclerosis with the monoclonal anti-CD4
346 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial.
347 *Neurology* 49, 351–357 (1997).
- 348 4. J. M. Gelfand, B. A. C. Cree, S. L. Hauser, Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in
349 Multiple Sclerosis. *Neurotherapeutics* 14, 835–841 (2017).

- 350 5. R. Li, K. R. Patterson, A. Bar-Or, Reassessing B cell contributions in multiple sclerosis. *Nat Immunol* 19, 696–
351 707 (2018).
- 352 6. S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S.
353 Agarwal, A. Langer-Gould, C. H. Smith, B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple
354 Sclerosis. *New England Journal of Medicine* 358, 676–688 (2008).
- 355 7. G. Comi, A. Bar-Or, H. Lassmann, A. Uccelli, H. Hartung, X. Montalban, P. S. Sørensen, R. Hohlfeld, S. L.
356 Hauser, Role of B Cells in Multiple Sclerosis and Related Disorders. *Ann Neurol* 89, 13–23 (2021).
- 357 8. D. S. W. Lee, O. L. Rojas, J. L. Gommerman, B cell depletion therapies in autoimmune disease: advances and
358 mechanistic insights. *Nat Rev Drug Discov* 20, 179–199 (2021).
- 359 9. P. A. Gordon, D. J. Carroll, W. S. Etches, V. Jeffrey, L. Marsh, B. L. Morrice, D. Olmstead, K. G. Warren, A
360 Double-blind Controlled Pilot Study of Plasma Exchange versus Sham Apheresis in Chronic Progressive Multiple
361 Sclerosis. *Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques* 12, 39–44
362 (1985).
- 363 10. B. G. Weinshenker, P. C. O’Brien, T. M. Petterson, J. H. Noseworthy, C. F. Lucchinetti, D. W. Dodick, A. A.
364 Pineda, L. N. Stevens, M. Rodriguez, A randomized trial of plasma exchange in acute central nervous system
365 inflammatory demyelinating disease. *Ann Neurol* 46, 878–886 (1999).
- 366 11. D. Pöhlau, H. Przuntek, M. Sailer, F. Bethke, J. Koehler, N. König, C. Heesen, P. Späth, I. Andresen,
367 Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo
368 controlled multicentre study. *Multiple Sclerosis Journal* 13, 1107–1117 (2007).
- 369 12. F. Fazekas, F. D. Lublin, D. Li, M. S. Freedman, H. P. Hartung, P. Rieckmann, P. S. Sorensen, M. Maas-
370 Enriquez, B. Sommerauer, K. Hanna, Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-
371 finding trial. *Neurology* 71, 265–271 (2008).
- 372 13. F. Fazekas, P. S. Sørensen, M. Filippi, S. Ropele, X. Lin, H. W. Koelmel, O. Fernandez, C. Pozzilli, P.
373 O’Connor, M. M. Enriquez, O. R. Hommes, MRI results from the European Study on Intravenous Immunoglobulin
374 in Secondary Progressive Multiple Sclerosis (ESIMS). *Multiple Sclerosis Journal* 11, 433–440 (2005).
- 375 14. M. Duddy, M. Niino, F. Adatia, S. Hebert, M. Freedman, H. Atkins, H. J. Kim, A. Bar-Or, Distinct Effector
376 Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis. *The Journal*
377 *of Immunology* 178, 6092–6099 (2007).
- 378 15. A. Bar-Or, L. Fawaz, B. Fan, P. J. Darlington, A. Rieger, C. Ghorayeb, P. A. Calabresi, E. Waubant, S. L.
379 Hauser, J. Zhang, C. H. Smith, Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? *Ann*
380 *Neurol* 67, 452–461 (2010).
- 381 16. T. A. Barr, P. Shen, S. Brown, V. Lampropoulou, T. Roch, S. Lawrie, B. Fan, R. A. O’Connor, S. M. Anderton,
382 A. Bar-Or, S. Fillatreau, D. Gray, B cell depletion therapy ameliorates autoimmune disease through ablation of IL-
383 6–producing B cells. *Journal of Experimental Medicine* 209, 1001–1010 (2012).
- 384 17. C. Blanco-Jerez, J. F. Plaza, J. Masjuan, L. M. Orensanz, J. C. Álvarez-Cermeño, Increased levels of IL-15
385 mRNA in relapsing–remitting multiple sclerosis attacks. *J Neuroimmunol* 128, 90–94 (2002).
- 386 18. M. Rentzos, C. Cambouri, A. Rombos, C. Nikolaou, M. Anagnostouli, A. Tsoutsou, A. Dimitrakopoulos, N.
387 Triantafyllou, D. Vassilopoulos, IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple
388 sclerosis. *J Neurol Sci* 241, 25–29 (2006).
- 389 19. R. Li, A. Rezk, Y. Miyazaki, E. Hilgenberg, H. Touil, P. Shen, C. S. Moore, L. Michel, F. Althekair, S.
390 Rajasekharan, J. L. Gommerman, A. Prat, S. Fillatreau, A. Bar-Or, Proinflammatory GM-CSF–producing B cells in
391 multiple sclerosis and B cell depletion therapy. *Sci Transl Med* 7 (2015), doi:10.1126/scitranslmed.aab4176.
- 392 20. Y. Miyazaki, R. Li, A. Rezk, H. Misirliyan, C. Moore, N. Farooqi, M. Solis, L. G. Goiry, O. de Faria Junior, V.
393 D. Dang, D. Colman, A. S. Dhaunchak, J. Antel, J. Gommerman, A. Prat, S. Fillatreau, A. Bar-Or, M. S. Horwitz,
394 Ed. A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with
395 Relapsing-Remitting Multiple Sclerosis. *PLoS One* 9, e105421 (2014).
- 396 21. D. Ghosh, W. Jiang, D. Mukhopadhyay, E. D. Mellins, New insights into B cells as antigen presenting cells.
397 *Curr Opin Immunol* 70, 129–137 (2021).
- 398 22. M. R. Lincoln, A. Montpetit, M. Z. Cader, J. Saarela, D. A. Dymment, M. Tiislar, V. Ferretti, P. J. Tienari, A. D.
399 Sadovnick, L. Peltonen, G. C. Ebers, T. J. Hudson, A predominant role for the HLA class II region in the association
400 of the MHC region with multiple sclerosis. *Nat Genet* 37, 1108–1112 (2005).
- 401 23. O. Olerup, J. Hillert, HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation.
402 *Tissue Antigens* 38, 1–15 (1991).
- 403 24. A. Spurkland, K. Skjold Rønningen, B. Vandvik, E. Thorsby, F. Vartdal, HLA-DQA1 and HLA-DQB1 genes
404 may jointly determine susceptibility to develop multiple sclerosis. *Hum Immunol* 30, 69–75 (1991).

- 405 25. C. Jersild, G. Hansen, A. Svejgaard, T. Fog, M. Thomsen, B. Dupont, HISTOCOMPATIBILITY
406 DETERMINANTS IN MULTIPLE SCLEROSIS, WITH SPECIAL REFERENCE TO CLINICAL COURSE. The
407 Lancet 302, 1221–1225 (1973).
- 408 26. D. G. Maloney, A. J. Grillo-López, D. J. Bodkin, C. A. White, T. M. Liles, I. Royston, C. Varns, J. Rosenberg,
409 R. Levy, IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
410 Journal of Clinical Oncology 15, 3266–3274 (1997).
- 411 27. A. Bar-Or, P. A. J. Calabresi, D. Arnold, C. Markowitz, S. Shafer, L. H. Kasper, E. Waubant, S. Gazda, R. J.
412 Fox, M. Panzara, N. Sarkar, S. Agarwal, C. H. Smith, Rituximab in relapsing-remitting multiple sclerosis: A 72-
413 week, open-label, phase I trial. Ann Neurol 63, 395–400 (2008).
- 414 28. T. Okada, V. N. Ngo, E. H. Ekland, R. Förster, M. Lipp, D. R. Littman, J. G. Cyster, Chemokine Requirements
415 for B Cell Entry to Lymph Nodes and Peyer's Patches. Journal of Experimental Medicine 196, 65–75 (2002).
- 416 29. S. J. Rodig, A. Shahsafaei, B. Li, C. R. Mackay, D. M. Dorfman, BAFF-R, the major B cell-activating factor
417 receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 36, 1113–1119
418 (2005).
- 419 30. L. Kappos, H.-P. Hartung, M. S. Freedman, A. Boyko, E. W. Radü, D. D. Mikol, M. Lamarine, Y. Hyvert, U.
420 Freudensprung, T. Plitz, J. van Beek, Atacept in multiple sclerosis (ATAMS): a randomised, placebo-controlled,
421 double-blind, phase 2 trial. Lancet Neurol 13, 353–363 (2014).
- 422 31. N. D. Huntington, R. Tomioka, C. Clavarino, A. M. Chow, D. Liñares, P. Maña, J. Rossjohn, T. G. Cachero, F.
423 Qian, S. L. Kalled, C. C. A. Bernard, H. H. Reid, A BAFF antagonist suppresses experimental autoimmune
424 encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 18, 1473–85 (2006).
- 425 32. X. Zhou, Z. Xia, Q. Lan, J. Wang, W. Su, Y.-P. Han, H. Fan, Z. Liu, W. Stohl, S. G. Zheng, A. Zernecke, Ed.
426 BAFF Promotes Th17 Cells and Aggravates Experimental Autoimmune Encephalomyelitis. PLoS One 6, e23629
427 (2011).
- 428 33. A. Cherukuri, P. C. Cheng, H. W. Sohn, S. K. Pierce, The CD19/CD21 Complex Functions to Prolong B Cell
429 Antigen Receptor Signaling from Lipid Rafts. Immunity 14, 169–179 (2001).
- 430 34. M. W. J. Wentink, M. C. van Zelm, J. J. M. van Dongen, K. Warnatz, M. van der Burg, Deficiencies in the
431 CD19 complex. Clinical Immunology 195, 82–87 (2018).
- 432 35. J. van Langelaar, L. Rijvers, J. Smolders, M. M. van Luijn, B and T Cells Driving Multiple Sclerosis: Identity,
433 Mechanisms and Potential Triggers. Front Immunol 11 (2020), doi:10.3389/fimmu.2020.00760.
- 434 36. X. Fan, T. Jin, S. Zhao, C. Liu, J. Han, X. Jiang, Y. Jiang, N. Fazilleau, Ed. Circulating CCR7+ICOS+ Memory
435 T Follicular Helper Cells in Patients with Multiple Sclerosis. PLoS One 10, e0134523 (2015).
- 436 37. J. Guo, C. Zhao, F. Wu, L. Tao, C. Zhang, D. Zhao, S. Yang, D. Jiang, J. Wang, Y. Sun, Z. Li, H. Li, K. Yang, T
437 Follicular Helper-Like Cells Are Involved in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
438 Front Immunol 9 (2018), doi:10.3389/fimmu.2018.00944.
- 439 38. A. E. Lovett-Racke, M. Gormley, Y. Liu, Y. Yang, C. Graham, S. Wray, M. K. Racke, R. Shubin, C. Twyman,
440 E. Alvarez, A. Bass, J. L. Eubanks, E. Fox, B cell depletion with ublituximab reshapes the T cell profile in multiple
441 sclerosis patients. J Neuroimmunol 332, 187–197 (2019).
- 442 39. E. S. Huseby, P. G. Huseby, S. Shah, R. Smith, B. D. Stadinski, Pathogenic CD8 T Cells in Multiple Sclerosis
443 and Its Experimental Models. Front Immunol 3 (2012), doi:10.3389/fimmu.2012.00064.
- 444 40. H. Babbe, A. Roers, A. Waisman, H. Lassmann, N. Goebels, R. Hohlfeld, M. Friese, R. Schröder, M. Deckert, S.
445 Schmidt, R. Ravid, K. Rajewsky, Clonal Expansions of CD8+ T Cells Dominate the T Cell Infiltrate in Active
446 Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction. Journal of
447 Experimental Medicine 192, 393–404 (2000).
- 448 41. M. Salou, A. Garcia, L. Michel, A. Gainche-Salmon, D. Loussouarn, B. Nicol, F. Guillot, P. Hulin, S. Nedellec,
449 D. Baron, G. Ramstein, J. Soullillou, S. Brouard, A. B. Nicot, N. Degauque, D. A. Laplaud, Expanded CD8 T-cell
450 sharing between periphery and CNS in multiple sclerosis. Ann Clin Transl Neurol 2, 609–622 (2015).
- 451 42. R. Q. Hintzen, René A. W. van Lier, K. C. Kuijpers, P. A. Baars, W. Schaasberg, C. J. Lucas, C. H. Polman,
452 Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis
453 patients. J Neuroimmunol 35, 211–217 (1991).
- 454 43. M. Komori, A. Blake, M. Greenwood, Y. C. Lin, P. Kosa, D. Ghazali, P. Winokur, M. Natrajan, S. C. Wuest, E.
455 Romm, A. A. Panackal, P. R. Williamson, T. Wu, B. Bielekova, Cerebrospinal fluid markers reveal intrathecal
456 inflammation in progressive multiple sclerosis. Ann Neurol 78, 3–20 (2015).
- 457 44. Y. Y. M. Wong, R. M. van der Vuurst de Vries, E. D. van Pelt, I. A. Ketelslegers, M.-J. Melief, A. F. Wierenga,
458 C. E. Catsman-Berrevoets, R. F. Neuteboom, R. Q. Hintzen, T-cell activation marker sCD27 is associated with
459 clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes. Multiple Sclerosis Journal 24,
460 1715–1724 (2018).

- 461 45. K. Agematsu, S. Hokibara, H. Nagumo, A. Komiyama, CD27: a memory B-cell marker. *Immunol Today* 21,
462 204–206 (2000).
- 463 46. B. K. Han, N. J. Olsen, A. Bottaro, The CD27–CD70 pathway and pathogenesis of autoimmune disease. *Semin*
464 *Arthritis Rheum* 45, 496–501 (2016).
- 465 47. S. M. A. Lens, K. Tesselaar, M. H. J. van Oers, R. A. W. van Lier, Control of lymphocyte function through
466 CD27–CD70 interactions. *Semin Immunol* 10, 491–499 (1998).
- 467 48. M. A. Nolte, R. W. van Olfen, K. P. J. M. van Gisbergen, R. A. W. van Lier, Timing and tuning of CD27-CD70
468 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology.
469 *Immunol Rev* 229, 216–231 (2009).
- 470 49. D. v Dolfi, A. C. Boesteanu, C. Petrovas, D. Xia, E. A. Butz, P. D. Katsikis, Late signals from CD27 prevent
471 Fas-dependent apoptosis of primary CD8+ T cells. *Journal of immunology* 180, 2912–21 (2008).
- 472 50. V. Peperzak, E. A. M. Veraar, A. M. Keller, Y. Xiao, J. Borst, The Pim Kinase Pathway Contributes to Survival
473 Signaling in Primed CD8+ T Cells upon CD27 Costimulation. *The Journal of Immunology* 185, 6670–6678 (2010).
- 474 51. J. Hendriks, L. A. Gravestein, K. Tesselaar, R. A. W. van Lier, T. N. M. Schumacher, J. Borst, CD27 is required
475 for generation and long-term maintenance of T cell immunity. *Nat Immunol* 1, 433–440 (2000).
- 476 52. J. Hendriks, Y. Xiao, J. Borst, CD27 Promotes Survival of Activated T Cells and Complements CD28 in
477 Generation and Establishment of the Effector T Cell Pool. *Journal of Experimental Medicine* 198, 1369–1380
478 (2003).
- 479 53. R. Q. Hintzen, S. M. Lens, K. Lammers, H. Kuiper, M. P. Beckmann, R. A. van Lier, Engagement of CD27 with
480 its ligand CD70 provides a second signal for T cell activation. *Journal of immunology* 154, 2612–23 (1995).
- 481 54. H. Oshima, Characterization of murine CD70 by molecular cloning and mAb. *Int Immunol* 10, 517–526 (1998).
- 482 55. L. A. Gravestein, J. D. Nieland, A. M. Kruisbeek, J. Borst, Novel mAbs reveal potent co-stimulatory activity of
483 murine CD27. *Int Immunol* 7, 551–557 (1995).
- 484 56. R. Q. Hintzen, R. de Jong, S. M. A. Lens, René A. W. van Lier, CD27: marker and mediator of T-cell activation?
485 *Immunol Today* 15, 307–311 (1994).
- 486 57. R. A. van Lier, J. Borst, T. M. Vroom, H. Klein, P. van Mourik, W. P. Zeijlemaker, C. J. Melief, Tissue
487 distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen.
488 *Journal of immunology* 139, 1589–96 (1987).
- 489 58. K. Kato, P. Chu, S. Takahashi, H. Hamada, T. J. Kipps, Metalloprotease inhibitors block release of soluble
490 CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. *Exp Hematol* 35, 434–
491 442 (2007).
- 492 59. W. A. M. Loenen, E. de Vries, L. A. Gravestein, R. Q. Hintzen, R. A. W. van Lier, J. Borst, The CD27
493 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a
494 soluble form by protein processing that does not involve receptor endocytosis. *Eur J Immunol* 22, 447–455 (1992).
- 495 60. F. Piehl, A. Eriksson-Dufva, A. Budzianowska, A. Feresiadou, W. Hansson, M. A. Hietala, I. Håkansson, R.
496 Johansson, D. Jons, I. Kmezic, C. Lindberg, J. Lindh, F. Lundin, I. Nygren, A. R. Punga, R. Press, K. Samuelsson,
497 P. Sundström, O. Wickberg, S. Brauner, T. Frisell, Efficacy and Safety of Rituximab for New-Onset Generalized
498 Myasthenia Gravis. *JAMA Neurol* (2022), doi:10.1001/jamaneurol.2022.2887.
- 499 61. R. J. Nowak, C. S. Coffey, J. M. Goldstein, M. M. Dimachkie, M. Benatar, J. T. Kissel, G. I. Wolfe, T. M.
500 Burns, M. L. Freimer, S. Nations, V. Granit, A. G. Smith, D. P. Richman, E. Ciafaloni, M. T. Al-Lozi, L. A. Sams,
501 D. Quan, E. Ubogu, B. Pearson, A. Sharma, J. W. Yankey, L. Uribe, M. Shy, A. A. Amato, R. Conwit, K. C.
502 O’Connor, D. A. Hafler, M. E. Cudkowicz, R. J. Barohn, Phase 2 Trial of Rituximab in Acetylcholine Receptor
503 Antibody-Positive Generalized Myasthenia Gravis. *Neurology* 98, e376–e389 (2022).
- 504 62. D. Hamann, P. A. Baars, M. H. G. Rep, B. Hooibrink, S. R. Kerkhof-Garde, M. R. Klein, R. A. W. van Lier,
505 Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells. *Journal of Experimental*
506 *Medicine* 186, 1407–1418 (1997).
- 507 63. R. M. van der Vuurst de Vries, J. Y. Mescheriakova, T. F. Runia, N. Jafari, T. A. M. Siepman, R. Q. Hintzen,
508 Soluble CD27 Levels in Cerebrospinal Fluid as a Prognostic Biomarker in Clinically Isolated Syndrome. *JAMA*
509 *Neurol* 74, 286 (2017).
- 510 64. M. Komori, Y. C. Lin, I. Cortese, A. Blake, J. Ohayon, J. Cherup, D. Maric, P. Kosa, T. Wu, B. Bielekova,
511 Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. *Ann Clin Transl Neurol* 3,
512 166–179 (2016).
- 513 65. J. Romme Christensen, M. Komori, M. R. von Essen, R. Ratzler, L. Börnsen, B. Bielekova, F. Sellebjerg, CSF
514 inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation
515 associated with axonal damage. *Multiple Sclerosis Journal* 25, 937–946 (2019).

- 516 66. M. R. Mahler, H. B. Søndergaard, S. Buhelt, M. R. von Essen, J. Romme Christensen, C. Enevold, F. Sellebjerg,
517 Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. *Mult Scler Relat Disord* 45, 102391
518 (2020).
- 519 67. A. Nakajima, H. Oshima, C. Nohara, S. Morimoto, S. Yoshino, T. Kobata, H. Yagita, K. Okumura, Involvement
520 of CD70–CD27 interactions in the induction of experimental autoimmune encephalomyelitis. *J Neuroimmunol* 109,
521 188–196 (2000).
- 522 68. S. Yanagisawa, N. Takeichi, T. Kaneyama, H. Yagita, S. Taniguchi, B. S. Kim, C.-S. Koh, Effects of anti-CD70
523 mAb on Theiler’s murine encephalomyelitis virus-induced demyelinating disease. *Brain Res* 1317, 236–245 (2010).
- 524 69. G. FrancoSalinas, T. Cantaert, M. A. Nolte, P. P. Tak, R. A. W. van Lier, D. L. Baeten, Enhanced costimulation
525 by CD70+ B cells aggravates experimental autoimmune encephalomyelitis in autoimmune mice. *J Neuroimmunol*
526 255, 8–17 (2013).
- 527 70. X. Zhang, R. Ge, H. Chen, M. Ahiafor, B. Liu, J. Chen, X. Fan, J. O. Martins, Ed. Follicular Helper CD4+ T
528 Cells, Follicular Regulatory CD4+ T Cells, and Inducible Costimulator and Their Roles in Multiple Sclerosis and
529 Experimental Autoimmune Encephalomyelitis. *Mediators Inflamm* 2021, 1–10 (2021).
- 530 71. D. F. Legler, M. Loetscher, R. S. Roos, I. Clark-Lewis, M. Baggiolini, B. Moser, B Cell-attracting Chemokine
531 1, a Human CXC Chemokine Expressed in Lymphoid Tissues, Selectively Attracts B Lymphocytes via
532 BLR1/CXCR5. *Journal of Experimental Medicine* 187, 655–660 (1998).
- 533 72. L. M. Ebert, P. Schaerli, B. Moser, Chemokine-mediated control of T cell traffic in lymphoid and peripheral
534 tissues. *Mol Immunol* 42, 799–809 (2005).
- 535 73. F. Sellebjerg, L. Bornsen, M. Khademi, M. Krakauer, T. Olsson, J. L. Frederiksen, P. S. Sorensen, Increased
536 cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. *Neurology* 73, 2003–2010 (2009).
- 537 74. M. Khademi, I. Kockum, M. L. Andersson, E. Iacobaeus, L. Brundin, F. Sellebjerg, J. Hillert, F. Piehl, T.
538 Olsson, Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
539 *Multiple Sclerosis Journal* 17, 335–343 (2011).
- 540 75. L. Piccio, R. T. Naismith, K. Trinkaus, R. S. Klein, B. J. Parks, J. A. Lyons, A. H. Cross, Changes in B- and T-
541 Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis. *Arch Neurol* 67, 707–714
542 (2010).
- 543 76. A. Corcione, S. Casazza, E. Ferretti, D. Giunti, E. Zappia, A. Pistorio, C. Gambini, G. L. Mancardi, A. Uccelli,
544 V. Pistoia, Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.
545 *Proceedings of the National Academy of Sciences* 101, 11064–11069 (2004).
- 546 77. M. Krumbholz, D. Theil, S. Cepok, B. Hemmer, P. Kivisäkk, R. M. Ransohoff, M. Hofbauer, C. Farina, T.
547 Derfuss, C. Hartle, J. Newcombe, R. Hohlfeld, E. Meinl, Chemokines in multiple sclerosis: CXCL12 and CXCL13
548 up-regulation is differentially linked to CNS immune cell recruitment. *Brain* 129, 200–211 (2006).
- 549 78. N. Schmitt, Role of T Follicular Helper cells in Multiple Sclerosis. *J Nat Sci* 1, e139 (2015).
- 550 79. A. J. Thompson, B. L. Banwell, F. Barkhof, W. M. Carroll, T. Coetzee, G. Comi, J. Correale, F. Fazekas, M.
551 Filippi, M. S. Freedman, K. Fujihara, S. L. Galetta, H. P. Hartung, L. Kappos, F. D. Lublin, R. A. Marrie, A. E.
552 Miller, D. H. Miller, X. Montalban, E. M. Mowry, P. S. Sorensen, M. Tintoré, A. L. Traboulsee, M. Trojano, B. M.
553 J. Uitdehaag, S. Vukusic, E. Waubant, B. G. Weinshenker, S. C. Reingold, J. A. Cohen, Diagnosis of multiple
554 sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol* 17, 162–173 (2018).
- 555 80. F. Ingelfinger, S. Krishnarajah, M. Kramer, S. G. Utz, E. Galli, M. Lutz, P. Zwicky, A. U. Akarca, N. P. Jurado,
556 C. Ulutekin, D. Bamert, C. C. Widmer, L. Piccoli, F. Sallusto, N. G. Núñez, T. Marafioti, D. Schreiter, I. Opitz, A.
557 Lanzavecchia, H. H. Jung, D. de Feo, S. Mundt, B. Schreiner, B. Becher, Single-cell profiling of myasthenia gravis
558 identifies a pathogenic T cell signature. *Acta Neuropathol* 141, 901–915 (2021).
- 559 81. F. Ingelfinger, L. A. Gerdes, V. Kavaka, S. Krishnarajah, E. Friebel, E. Galli, P. Zwicky, R. Furrer, C. Peukert,
560 C.-A. Dutertre, K. M. Eglseer, F. Ginhoux, A. Flierl-Hecht, T. Kümpfel, D. de Feo, B. Schreiner, S. Mundt, M.
561 Kerschensteiner, R. Hohlfeld, E. Beltrán, B. Becher, Twin study reveals non-heritable immune perturbations in
562 multiple sclerosis. *Nature* 603, 152–158 (2022).
- 563 82. R. Finck, E. F. Simonds, A. Jager, S. Krishnaswamy, K. Sachs, W. Fantl, D. Pe’er, G. P. Nolan, S. C. Bendall,
564 Normalization of mass cytometry data with bead standards. *Cytometry Part A* 83A, 483–494 (2013).
- 565 83. S. van Gassen, B. Gaudilliere, M. S. Angst, Y. Saeys, N. Aghaepour, CytoNorm: A Normalization Algorithm
566 for Cytometry Data. *Cytometry Part A* 97, 268–278 (2020).
- 567 84. S. van Gassen, B. Callebaut, M. J. van Helden, B. N. Lambrecht, P. Demeester, T. Dhaene, Y. Saeys, FlowSOM:
568 Using self-organizing maps for visualization and interpretation of cytometry data. *Cytometry Part A* 87, 636–645
569 (2015).
- 570 85. M. D. Wilkerson, D. N. Hayes, ConsensusClusterPlus: a class discovery tool with confidence assessments and
571 item tracking. *Bioinformatics* 26, 1572–1573 (2010).

572 86. L. McInnes, J. Healy, N. Saul, L. Großberger, UMAP: Uniform Manifold Approximation and Projection. J Open
573 Source Softw 3, 861 (2018).

574

575 **Acknowledgments:** We thank all the patients that participated in the study. We thank Catarina
576 Raposo for the helpful review of the manuscript.

577 **Funding:** This work received project funding from Roche Pharma (to B.B.) and from the European
578 Research Council (ERC) under the European Union's Horizon 2020 research and innovation
579 program grant agreement no. 882424 (to B.B.), the Swiss National Science Foundation (733
580 310030_170320, 310030_188450 and CRSII5_183478 to B.B.), as well as the Swiss MS Society
581 Research grant (to F.I.); F.I. received a PhD fellowship from the Studienstiftung des deutschen
582 Volkes. T.O. has grant support from the Swedish Research council, the Knut and Alice Wallenberg
583 foundation, the Swedish Brain Foundation and Margaretha af Ugglas Foundation.

584 **Author contributions:** E.G. and F.I. generated the mass cytometry data. C.U. analyzed all the
585 data. I.C., M.K., F.P., N.S., R.F., T.O. and T.D. performed clinical characterization of the cohorts
586 and provided patient samples and clinical input. B.B. and F.I. jointly supervised the study. B.B.
587 funded the study. C.U., F.I. and B.B. wrote the manuscript.

588 **Competing interests:** This study was partially funded by Roche Pharma. T.O. has received
589 advisory board/lecture honoraria and unrestricted MS research grants from Biogen, Sanofi, Merck,
590 and Novartis, none of which has any relation to the current study. Other than that, the authors
591 declare no conflict of interest.

592 **Data and materials availability:** Mass cytometry data of the discovery and validation cohort will
593 be made publicly available upon publication. Custom analysis code to reproduce the analysis will
594 be uploaded to a public repository.